Ledipasvir and sofosbuvir

Ledipasvir and sofosbuvir is a medication used in the treatment of hepatitis C. It is a combination of two antiviral drugs, ledipasvir and sofosbuvir. The medication is taken orally, and it is available under the brand name Harvoni.

Mechanism of Action[edit | edit source]

Ledipasvir is an NS5A inhibitor, which means it blocks a protein that the hepatitis C virus needs to replicate. Sofosbuvir is a nucleotide analogue that inhibits the NS5B polymerase, another protein necessary for the virus to reproduce.

Uses[edit | edit source]

Ledipasvir and sofosbuvir is used to treat chronic hepatitis C infection. It is effective against genotypes 1, 4, 5, and 6 of the virus. The medication is typically used in combination with other antiviral drugs.

Side Effects[edit | edit source]

Common side effects of ledipasvir and sofosbuvir include fatigue, headache, and nausea. More serious side effects can include a slow heart rate and reactivation of hepatitis B in those who have previously been infected with this virus.

History[edit | edit source]

Ledipasvir and sofosbuvir was approved for medical use in the United States in 2014. It was developed by Gilead Sciences, and it is marketed under the brand name Harvoni.

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.